IP77-16: Spatial Immunophenotypes Combined with Neutrophil-to-Lymphocyte Ratio (NLR) Predict Response to Immune Checkpoint Inhibitors (ICIs) and Gemcitabine-Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

IP77-16: Spatial Immunophenotypes Combined with Neutrophil-to-Lymphocyte Ratio (NLR) Predict Response to Immune Checkpoint Inhibitors (ICIs) and Gemcitabine-Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!